1. What Do We Know About LDL-C?

4. Hospital Discharges for Patients With CVD

6. Estimate of the Association of Genetically Raised LDL-C or HDL-C and Risk of MI Using Multiple Genetic Variants as Instruments

7. Effect of Lower LDL-C on the Risk of CHD Mediated by Genetic Polymorphism

8. Relationship Between Cumulative LDL-C Exposure and Age

9. Comparison of Recent Major Guidelines

10. NLA Recommendations

11. Relationship Between LDL-C Reduction and CHD Relative Risk

12. Effect on CHD Events of Lowering LDL-C

13. IMPROVE-IT Enrollment and Study Period

14. IMPROVE-IT Efficacy

15. ODYSSEY Long-Term Study LDL-C Reduction Over Time

16. ODYSSEY Long-Term Study MACE Outcomes

17. LDL-C Change: Evolocumab vs Standard Therapy

18. Evolocumab Cumulative Incidence of CV Events

20. Guidance for Use of PSCK9 Inhibitors*

22. CETP Inhibitors: HDL-C and LDL-C Effects and Current Status

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)